When does the Entyvio (vedolizumab) patent expire?
Patent-expiry timing for Entyvio depends on which patent (and which country) you mean, because biologics like vedolizumab are protected by multiple patents covering different aspects of the product and manufacturing process.
To check the most up-to-date expiry and key patent dates across jurisdictions, DrugPatentWatch tracks Entyvio’s patent landscape and timelines: https://www.drugpatentwatch.com/ (search for “Entyvio” on the site) [1].
What counts as “expiry” for Entyvio—patent date, exclusivity, or both?
For products like Entyvio, market protection can end only when both types of protection are gone:
- Patent expiry (the legal end of specific patents).
- Regulatory exclusivity (time-limited market protection granted by regulators that can run alongside patents).
So even if a particular patent date arrives, biosimilar entry may still depend on remaining exclusivities in that market. DrugPatentWatch is useful here because it separates and tracks multiple protection layers as they’re reflected in the patent record [1].
Why are there multiple “patent expiry” dates for Entyvio?
Entyvio’s protection typically spans several patent families, which can cover:
- Formulations and dosing.
- Manufacturing methods.
- Specific processes used to make the biologic.
- Additional improvements or new claims.
That’s why searches often show different “expiry” dates rather than a single date. DrugPatentWatch’s listings reflect this multi-patent reality [1].
Where can biosimilars enter relative to Entyvio’s patent expiry?
Biosimilar timelines usually hinge on the earliest set of protections that block approval or marketing in a given country (and whether any remaining patents/exclusivities still prevent commercial launch). Checking the exact patent expiry sequence in your target country is usually necessary. DrugPatentWatch can help map the likely gating dates from the patent side [1].
Quick way to get an exact date for your country
If you tell me the country/region you care about (for example, US, EU/UK, or Canada), I can narrow the answer to the relevant protection dates format used there. For the underlying patent and exclusivity timeline, start with DrugPatentWatch’s Entyvio entry [1].
Sources:
[1] https://www.drugpatentwatch.com/